These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33357364)

  • 1. [Role of astrocytic connexins in the regulation of extracellular glutamate levels: implication for the treatment of major depressive episodes].
    Portal B; Guiard BP
    Biol Aujourdhui; 2020; 214(3-4):71-83. PubMed ID: 33357364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
    Quesseveur G; Gardier AM; Guiard BP
    Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mechanism of depression: role for connexins.
    Xia CY; Wang ZZ; Yamakuni T; Chen NH
    Eur Neuropsychopharmacol; 2018 Apr; 28(4):483-498. PubMed ID: 29519610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
    Lener MS; Niciu MJ; Ballard ED; Park M; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2017 May; 81(10):886-897. PubMed ID: 27449797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astroglial Connexins Inactivation Increases Relapse of Depressive-like Phenotype after Antidepressant Withdrawal.
    Portal B; Vasile F; Zapata J; Lejards C; Ait Tayeb AEK; Colle R; Verstuyft C; Corruble E; Rouach N; Guiard BP
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glutamatergic neurotransmission, depression and antidepressants].
    Ferrero A; Cereseto M
    Vertex; 2004; 15(56):91-8. PubMed ID: 15243652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder.
    Sarrouilhe D; Mesnil M; Dejean C
    Curr Med Chem; 2019; 26(20):3775-3791. PubMed ID: 29589532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The many ways astroglial connexins regulate neurotransmission and behavior.
    Mazaud D; Capano A; Rouach N
    Glia; 2021 Nov; 69(11):2527-2545. PubMed ID: 34101261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perisynaptic astrocytes as a potential target for novel antidepressant drugs.
    Frizzo ME; Ohno Y
    J Pharmacol Sci; 2021 Jan; 145(1):60-68. PubMed ID: 33357781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH; Gardier AM
    Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connexin 43: insights into candidate pathological mechanisms of depression and its implications in antidepressant therapy.
    Zhang NN; Zhang Y; Wang ZZ; Chen NH
    Acta Pharmacol Sin; 2022 Oct; 43(10):2448-2461. PubMed ID: 35145238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.
    Tomasetti C; Montemitro C; Fiengo ALC; Santone C; Orsolini L; Valchera A; Carano A; Pompili M; Serafini G; Perna G; Vellante F; Martinotti G; Giannantonio MD; Kim YK; Nicola MD; Bellomo A; Ventriglio A; Fornaro M; Berardis DD
    Curr Pharm Des; 2019; 25(4):381-387. PubMed ID: 30864501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astroglial networks scale synaptic activity and plasticity.
    Pannasch U; Vargová L; Reingruber J; Ezan P; Holcman D; Giaume C; Syková E; Rouach N
    Proc Natl Acad Sci U S A; 2011 May; 108(20):8467-72. PubMed ID: 21536893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications.
    Jezova D
    Endocrine; 2005 Dec; 28(3):287-94. PubMed ID: 16388118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual symptoms in depression an emerging therapeutic concept.
    Sonino N; Fava GA
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):763-70. PubMed ID: 12188108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.